Elanco Animal Health IncELANEarnings & Financial Report
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
ELAN Q4 FY2025 Key Financial Metrics
Revenue
$1.1B
Gross Profit
$589.0M
Operating Profit
$-259.0M
Net Profit
$-276.0M
Gross Margin
51.5%
Operating Margin
-22.6%
Net Margin
-24.1%
YoY Growth
12.2%
EPS
$-0.55
Elanco Animal Health Inc Q4 FY2025 Financial Summary
Elanco Animal Health Inc reported revenue of $1.1B (up 12.2% YoY) for Q4 FY2025, with a net profit of $-276.0M (down 3350.0% YoY) (-24.1% margin). Cost of goods sold was $555.0M, operating expenses totaled $848.0M.
Key Financial Metrics
| Total Revenue | $1.1B |
|---|---|
| Net Profit | $-276.0M |
| Gross Margin | 51.5% |
| Operating Margin | -22.6% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Elanco Animal Health Inc Q4 FY2025 revenue of $1.1B breaks down across 5 segments, led by Pet Health at $489.0M (42.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Pet Health | $489.0M | 42.7% |
| Cattle | $296.0M | 25.9% |
| Poultry | $237.0M | 20.7% |
| Swine | $107.0M | 9.4% |
| Contract Manufacturing | $15.0M | 1.3% |
Elanco Animal Health Inc Revenue by Segment — Quarterly Trend
Elanco Animal Health Inc revenue by segment across the last 4 reported quarters, showing how each business line (such as Pet Health and Cattle) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Pet Health | $489.0M | $533.0M | $643.0M | $635.0M |
| Cattle | $296.0M | $289.0M | $268.0M | $272.0M |
| Poultry | $237.0M | $217.0M | $215.0M | $189.0M |
| Swine | $107.0M | $87.0M | $100.0M | $85.0M |
| Contract Manufacturing | $15.0M | $11.0M | $15.0M | $12.0M |
Elanco Animal Health Inc Annual Revenue by Year
Elanco Animal Health Inc annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.7B).
Elanco Animal Health Inc Quarterly Revenue & Net Profit History
Elanco Animal Health Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.1B | +12.2% | $-276.0M | -24.1% |
| Q3 FY2025 | $1.1B | +10.4% | $-34.0M | -3.0% |
| Q2 FY2025 | $1.2B | +4.8% | $11.0M | 0.9% |
| Q1 FY2025 | $1.2B | -1.0% | $67.0M | 5.6% |
| Q4 FY2024 | $1.0B | -1.4% | $-8.0M | -0.8% |
| Q3 FY2024 | $1.0B | -3.6% | $364.0M | 35.3% |
| Q2 FY2024 | $1.2B | +12.0% | $-50.0M | -4.2% |
| Q1 FY2024 | $1.2B | -4.1% | $32.0M | 2.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.18B | $1.03B | $1.02B | $1.19B | $1.24B | $1.14B | $1.14B |
| YoY Growth | -4.1% | 12.0% | -3.6% | -1.4% | -1.0% | 4.8% | 10.4% | 12.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $14.02B | $13.76B | $13.28B | $12.61B | $12.94B | $13.74B | $13.55B | $13.36B |
| Liabilities | $7.96B | $7.82B | $6.76B | $6.52B | $6.59B | $6.97B | $6.80B | $6.81B |
| Equity | $6.06B | $5.94B | $6.52B | $6.10B | $6.35B | $6.78B | $6.75B | $6.55B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $2.0M | $200.0M | $162.0M | $177.0M | $-4.0M | $237.0M | $219.0M | $108.0M |